The present application relates to a diagnostic composition comprising: a. a compound of Formula I,

##STR00001## b. ethanol, c. water, and d. a hydroxycarboxylic acid, a salt of a hydroxycarboxylic acid or a mixture thereof.

The diagnostic composition can be used in the selective detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease (AD) and other tauopathies, for example, using Positron Emission Tomography (PET). The present invention also relates to a method of preparing the claimed diagnostic composition.

The present invention relates to novel compounds of the formula (II)

##STR00001##

that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission Tomography (PET) Imaging. The present invention also discloses intermediates which are useful in the preparation of these compounds.

The present invention relates to a novel method of preparing a compound of the formula I. Diagnostic compositions and their use in the selective detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease (AD) and other tauopathies, for example, using Positron Emission Tomography (PET) imaging are also disclosed.

Provided are a compound represented by the following formula (1):

##STR00001##

wherein X.sub.1 represents a hydrogen atom or a halogen atom, X.sub.2 represents a fluorine atom or a nitrile group, and X.sub.3 represents a radioactive halogen atom, or a salt thereof, and a medicament including the same.

Radiofluorinated FNDP for PET imaging of soluble epoxide hydrolase (sEH) and method of using the same are disclosed.

Methods, and related compositions, for the improved synthesis of [.sup.18F]DCFPyL are disclosed. Also provided are methods, and related compositions, for the use of [.sup.18F]DCFPyL so produced.

The present application relates to conduritol aziridines of Formula (I), and uses thereof, for example, of .sup.18F-labelled derivatives thereof in positron-emission tomography (PET) imaging of -glucocerebrosidase activity.

##STR00001##

The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.

Provided herein are isotopologues of Compound A, which are enriched with isotopes such as, for example, deuterium. Pharmaceutical compositions comprising the isotope-enriched compounds, and methods of using such compounds are also provided.

The present invention relates to a compound of formula (I), a pharmaceutical composition comprising or consisting of said compound, a kit comprising or consisting of said compound or pharmaceutical composition and use of the compound or pharmaceutical composition in the diagnosis or treatment of a disease characterized by overexpression of fibroblast activation protein (FAP).

##STR00001##